Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension

American Journal of Preventive Cardiology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles